MARKET

REGN

REGN

Regeneron Pharmaceuticals
NASDAQ
749.47
+7.78
+1.05%
Closed 19:27 03/25 EDT
OPEN
744.67
PREV CLOSE
741.69
HIGH
757.98
LOW
744.02
VOLUME
553.09K
TURNOVER
313.82M
52 WEEK HIGH
820.12
52 WEEK LOW
474.60
MARKET CAP
79.23B
P/E (TTM)
18.07
1D
5D
1M
3M
1Y
5Y
1D
Regeneron to report first-quarter 2026 results; conference call and webcast set for 8:30 a.m. ET
Reuters · 20h ago
The Bull Case For Regeneron Pharmaceuticals (REGN) Could Change Following New Japanese Dupixent BP Approval
Simply Wall St · 1d ago
Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone
Seeking Alpha · 2d ago
Regeneron, Sanofi get approval for Dupixent to treat bullous pemphigoid in Japan
TipRanks · 2d ago
Regeneron And Sanofi's Dupixent Approved In Japan As First Targeted Medicine For Adults With Moderate-To-Severe Bullous Pemphigoid
Benzinga · 2d ago
Japan MHLW approves Dupixent for moderate-to-severe bullous pemphigoid adults
Reuters · 2d ago
PRESS RELEASE: SANOFI AND REGENERON’S DUPIXENT APPROVED IN JAPAN AS THE FIRST TARGETED MEDICINE TO TREAT ADULTS WITH BULLOUS PEMPHIGOID
Reuters · 2d ago
DUPIXENT® (DUPILUMAB) APPROVED IN JAPAN AS THE FIRST TARGETED MEDICINE TO TREAT ADULTS WITH BULLOUS PEMPHIGOID (BP)
Reuters · 2d ago
More
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Webull offers Regeneron Pharmaceuticals Inc stock information, including NASDAQ: REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.